Wanbury Limited
Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

WANBURY

July 22, 2026

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. **Scrip Code: 524212**	To, National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (East), Mumbai 400 051 **Scrip Code: WANBURY**

Dear Sir,

Sub.: Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Company's facility at Tanuku, West Godavari District, Andhra Pradesh

Further to our letter dated 20th July, 2026, we hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility at Tanuku, West Godavari District, Andra Pradesh during the period from July 13, 2026 to July 17, 2026.

At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time.

The relevant disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in **ANNEXURE – I** below.

We will keep the stock exchanges informed if there is any further update in this matter.

Please take the above information on record.

Thanking you,

Yours truly
For Wanbury Limited

JITENDRA
JAYANTILAL
GANDHI

Digitally signed by JITENDRA JAYANTILAL GANDHI
DN: c=IN, postalCode=400092, st=MAHARASHTRA, street=12-D15, 3RD FLOOR, ESTEE APARTMENT ,SAIBABA NAGAR ,MUMBAI,BORIVALI WEST ,400092, l=MUMBAI, o=Personal, serialNumber=dd7bf68d2d33b1a0b2c1c9ea066064ac87ac5fbfc7dbca1ff8702008cecc8cef, pseudonym=f9c60cbabe0f41cca990c8873b3c1d17, 2.5.4.20=265ffb5da821684560ea15e545a517df8af595a3473eca632336e7b57b06b286, email=JITENDRA.GANDHI@WANBURY.COM, cn=JITENDRA JAYANTILAL GANDHI
Date: 2026.07.22 15:04:12 +05'30'

Jitendra J Gandhi
Company Secretary

Encl.: a/a.

WANBURY

ANNEXURE - I

Details of the action initiated by USFDA in the prescribed format as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particulars	Details
1.	Name of the authority	United States Food and Drug Administration (USFDA), USA.
2.	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at the Company's facility at Tanuku, West Godavari District, Andhra Pradesh during the period from July 13, 2026 to July 17, 2026. At the conclusion of the inspection, the USFDA issued a Form 483 with six observations. The Company will respond to these observations within the stipulated time.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	July 17, 2026
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	At the conclusion of the inspection, the USFDA issued a Form 483 with six observations. The Company will respond to these observations within the stipulated time.
5.	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	A preliminary assessment of the observations indicates that all the observations are addressable with appropriate supporting documentation, corrective actions, technical justification and procedural enhancements. Based on the nature of these observations, the Company does not anticipate any impact to its manufacturing operations or exports to the Unites States and other international markets. Accordingly, the Company does not expect any material impact on its operations or financial performance arising from this inspection. The Company remains committed to maintain the highest standards of quality and compliance with current Good Manufacturing Practices (cGMP).

WANBURY LIMITED